Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Katharine Harding

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
JAMA Neurology|February 19, 2019
Clinical Outcomes of Escalation vs Early Intensive Disease-Modifying Therapy in Patients With Multiple SclerosisKatharine Harding, Owain Williams, Mark Willis, et al.
Journal of Neurology|April 21, 2017
Seasonal variation in multiple sclerosis relapseKatharine Harding, Kate Tilling, Claire MacIver, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|May 19, 2023
Real-world annualized relapse rates from contemporary multiple sclerosis clinics in the UK: a retrospective multicentre cohort studyAthanasios Papathanasiou, Aimee Hibbert, Emma Tallantyre, et al.
European Journal of Neurology|February 9, 2026
MOGAD in South Wales: Diagnostic Evolution and Disease EpidemiologySophie Voase, Patrick Waters, Stephen Jolles, et al.
Journal of the Neurological Sciences|May 20, 2020
Seasonal distribution of attacks in aquaporin-4 antibody disease and myelin-oligodendrocyte antibody diseaseGiordani Rodrigues Dos Passos, Liene Elsone, Sebastian Luppe, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|May 23, 2014
Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacyOrla Tuohy, Lisa Costelloe, Grant Hill-Cawthorne, et al.
JAMA|January 16, 2019
Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple SclerosisJ William L Brown, Alasdair Coles, Dana Horakova, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
JAMA Neurology|February 19, 2019
Clinical Outcomes of Escalation vs Early Intensive Disease-Modifying Therapy in Patients With Multiple SclerosisKatharine Harding, Owain Williams, Mark Willis, et al.
Journal of Neurology|April 21, 2017
Seasonal variation in multiple sclerosis relapseKatharine Harding, Kate Tilling, Claire MacIver, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|May 19, 2023
Real-world annualized relapse rates from contemporary multiple sclerosis clinics in the UK: a retrospective multicentre cohort studyAthanasios Papathanasiou, Aimee Hibbert, Emma Tallantyre, et al.
European Journal of Neurology|February 9, 2026
MOGAD in South Wales: Diagnostic Evolution and Disease EpidemiologySophie Voase, Patrick Waters, Stephen Jolles, et al.
Journal of the Neurological Sciences|May 20, 2020
Seasonal distribution of attacks in aquaporin-4 antibody disease and myelin-oligodendrocyte antibody diseaseGiordani Rodrigues Dos Passos, Liene Elsone, Sebastian Luppe, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|May 23, 2014
Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacyOrla Tuohy, Lisa Costelloe, Grant Hill-Cawthorne, et al.
JAMA|January 16, 2019
Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple SclerosisJ William L Brown, Alasdair Coles, Dana Horakova, et al.
Pageof 2